Vaccination in pediatric rheumatic disease—risks and benefits

Janow, Ginger; Ilowite, Norman T.

doi:10.1038/nrrheum.2012.13

Cited by 3 publications

(2 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Vaccination is highly speci fic, inexpensive and safe in healthy paedi atric populations and is, therefore, one of the main tools used to reduce the morbidity associated with viral and bac terial infections. 1,2 Live and nonlive vaccines are included in routine paediatric vaccination programs worldwide. However, immunization of patients with childhood inflammatory conditions is somewhat controversial, particularly because of concerns over vaccine safety and effectiveness, related to the distinct disease manifestations and their respective treatments.…”

Section: Introductionmentioning

confidence: 99%

Vaccinations in juvenile chronic inflammatory diseases: an update

2013

View full text Add to dashboard Cite

Vaccination is a powerful tool to reduce the burden of infectious diseases in paediatric patients with chronic rheumatic diseases. Live attenuated vaccines are not recommended for profoundly immunosuppressed patients, but nonlive vaccines have adequate safety and efficacy profiles in the few (admittedly underpowered) studies published to date. No severe vaccine-specific or disease-specific adverse events have been observed in patients with juvenile idiopathic arthritis (JIA) or childhood-onset systemic lupus erythematosus (SLE) who have been vaccinated with live or nonlive agents. The immune response to live vaccines is variable in these patients but generally adequate, despite concomitant use of immunosuppressive and biologic agents. The proposal that onset of autoimmune rheumatic diseases could be induced by vaccination is controversial and primarily based on case reports; however, patients with mevalonate kinase deficiency can experience febrile attacks after immunizations. Adequately powered studies of live and nonlive vaccination in patients with paediatric rheumatic diseases are necessary to clarify safety and efficacy issues. This narrative Review discusses vaccination in patients with JIA, childhood-onset SLE, juvenile dermatomyositis, juvenile systemic sclerosis, primary vasculitis and autoinflammatory syndromes. Vaccine safety, short-term and long-term changes in disease parameters, and the immunogenicity and influence of immunosuppressive agents are outlined for each combination of disease and vaccine.

show abstract

Section: Introductionmentioning

confidence: 99%

Vaccinations in juvenile chronic inflammatory diseases: an update

2013

View full text Add to dashboard Cite

show abstract

“…Although great efforts have been made to improve vaccination completion by vaccinators’ and medical staff’s regular and scientific immunization recommendations, inconsistencies with published suggestions and factors potentially affecting the vaccination decision have led to differences in clinical practice. 7 Some case reports described the adverse events following immunization (AEFI) observed in patients with PRDs, primarily including IgA vasculitis (IgAV) and Kawasaki disease (KD). 8–10 Some researchers depicted the vaccination status in Chinese patients with inflammatory bowel disease, spinal muscular atrophies, and other adult chronic rheumatic diseases.…”

Section: Introductionmentioning

confidence: 99%

Knowledge and practices of vaccination for children with rheumatic diseases: A single-center study in China

Luo

Jiang

Pang

et al. 2023

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Patients with pediatric rheumatic diseases (PRDs) have higher morbidity and mortality associated with infectious diseases. Vaccination is an effective way to prevent infection. This study aimed to understand the vaccination status, vaccination-related attitudes, and adverse reactions in patients with PRDs in one of the largest Pediatric Rheumatic and Immune centers in China. A cross-sectional study using an online questionnaire was conducted among the caregivers of patients with PRDs admitted to the Children’s Hospital of Chongqing Medical University. 189 valid questionnaires were collected. The most two common PRDs in this study were juvenile idiopathic arthritis (29.6%) and systemic lupus erythematosus (19.6%). Univariate analysis and multivariate logistic regression were used to identify potential factors associated with vaccination completion among these patients. Univariate analysis suggested that the age of onset, course of the disease, treatment duration, disease duration <1 month, disease duration ≥24 months, treatment duration <1 month, use of biological agents, at least one hospitalization, whether with one-time intravenous human immunoglobulin, caregiver concerns about vaccination before or after illness, and vaccine hesitancy may affect the scheduled vaccination completion by age in patients ( p < .05). Multivariate logistic regression analysis showed that the age of onset (OR, 1.013; 95% CI, 1.005–1.022; p = .002) and caregiver concerns about vaccination before illness (OR, 0.600; 95% CI, 0.428–0.840; p = .003) independently influenced patients’ completion of scheduled vaccinations. This study suggests that rheumatic disease and treatment may influence age-appropriate vaccination. Appropriate education for patients and carers may improve vaccination cognition and attitudes.

show abstract

Pharmacology

Ilowite¹,

Laxer²

2016

Textbook of Pediatric Rheumatology

View full text Add to dashboard Cite

Vaccination in pediatric rheumatic disease—risks and benefits

Cited by 3 publications

References 10 publications

Vaccinations in juvenile chronic inflammatory diseases: an update

Vaccinations in juvenile chronic inflammatory diseases: an update

Knowledge and practices of vaccination for children with rheumatic diseases: A single-center study in China

Pharmacology

Contact Info

Product

Resources

About